ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 2576

Glucagon-Like Peptide-1 Receptor Agonist Use and the Risk of Adverse Cardiac and Kidney Outcomes Among Patients with Systemic Lupus Erythematosus and Lupus Nephritis
Abstract Number: 2577

Efficacy and Safety of ABBV-599 (Elsubrutinib and Upadacitinib Combination) and Upadacitinib Monotherapy for the Treatment of Systemic Lupus Erythematosus: Results Through 104 Weeks in a Long-Term Extension Study
Abstract Number: 2578

Safety, Biomarker Response, and Efficacy of E6742, a Dual Antagonist of Toll-Like Receptor 7 and 8, in a First-in-Patient, Randomized, Double-Blind, Phase1/2 Study in Systemic Lupus Erythematosus
Abstract Number: 2579

Risk of End-Stage Renal Disease Among Patients with Lupus Nephritis on GLP-1 Receptor Agonists: A Retrospective Cohort Study
Abstract Number: 2580

Safety and Efficacy of Subcutaneous Ianalumab (VAY736) for up to 68 Weeks in Patients with Systemic Lupus Erythematosus: Results from Phase 2 Study
Abstract Number: 2581

Vunakizumab in Patients with Active Psoriatic Arthritis: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study
Abstract Number: 2582

Efficacy and Safety of Sonelokimab, a Novel IL-17A- and IL-17F-Inhibiting Nanobody, in Patients with Active PsA: 24-Week Results from a Global, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
Abstract Number: 2583

Apremilast Reduces Axial Inflammation in Patients with Psoriatic Arthritis as Assessed by CANDEN MRI Scoring: Results from a Phase 4 Study
Abstract Number: 2584

Zasocitinib (TAK-279), an Oral, Selective Tyrosine Kinase 2 Inhibitor: Achievement of Remission and Additional Improvements in Disease Activity in Patients with Psoriatic Arthritis Enrolled in a Phase 2b Trial
Abstract Number: 2585

Guselkumab and IL-17 Inhibitors Improve Patient-perceived Impact of Psoriatic Arthritis Similarly: 6-month Interim Results of the PsABIOnd Observational Cohort Study
Abstract Number: 2586

Results from the Biopsy Driven Ebio Study: Entheseal Tissue Signature in Response to IL-17 Blockade in Psoriatic Arthritis
Abstract Number: 2587

A Proprietary AI Rule Engine Assisted by an OpenAI-based ML Model Can Speed up and Better Inform the Prior Authorization Process for Rheumatology Investigations and Medications
Abstract Number: 2588

Examining the Influence of Socioeconomic Status on Osteoarthritis Prevalence and Risk Factors Among New York Residents
Abstract Number: 2589

A Nationwide Analysis of Risk of Acute Coronary Syndrome in RA Patients with Interstitial Lung Disease
Abstract Number: 2590

Pesticide Use and Incident Rheumatoid Arthritis Among Spouses in the Agricultural Health Study: An Updated Analysis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].